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Abstract
Adenoid cystic carcinoma (ACC) is characterized by slow growth, frequent local recurrences, and high incidence of distant
metastasis (DM). The aim of this study was to evaluate predictive factors for local-regional (LR) recurrence, DM, and survival
in ACC.
A retrospective review of the medical records for patients with salivary glands ACC from 1990 to 2015 was performed. The clinical
parameters were assessed to identify correlations with the development of LR recurrence, DM, and survival of these patients.
Among 228 patients who underwent surgery as deﬁnitive treatment, 210 (92.1%) were followed up in the study. DMwas detected
in 64 (30.5%) patients, LR recurrence was detected in 58 (27.6%) patients. The estimated 5, 10, and 15-year overall survival rates
were 84.7%, 70.8%, and 34.0%, respectively. Multivariate analysis revealed that the presence of lymphovascular invasion and a high
T classiﬁcation were very strong adverse factors, which independently inﬂuenced LR recurrence, DM, and survival of ACC patients.
Positive/close margin and N+ status were independent risk factors for DM and LR recurrence, respectively. Survival of ACC patents
was also affected by tumor location.
Presence of lymphovascular invasion and a high T classiﬁcation were very strong adverse factors and independent predictors for
ACC patients’ prognosis, which inﬂuenced LR control, DM control, and survival.
Abbreviations: ACC = adenoid cystic carcinoma, DM = distant metastasis, LR = local-regional, OS = overall survival, RT =
radiotherapy.
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11. Introduction
Adenoid cystic carcinoma (ACC) is a rare tumor accounting for
approximately less than 1% of all malignant tumors of the head
and neck.[1,2] Yet, it is the most common malignant tumor in the
minor salivary glands and 2nd most frequent malignancy in the
major salivary glands.[3,4] ACC is characterized by an indolent
but persistent course, with high rates of both local-regional (LR)
recurrence and distant metastasis (DM)[5,6] that can develop even
many years after initial treatment of primary tumor. DM is
reported in up to 52% of ACC patients[7] and can occur with/
without LR recurrence.[8] Although most patients with ACC are
alive at 5 years, a majority of patients die from their disease 5 to
20 years after diagnosis.[6,8] The long-term outcomes continue to
be guarded, with an estimated 10-year overall survival (OS) of
<70%.[8–10] Therefore, understanding more about patient and
tumor characteristics in regards to prognosis is critical.
Due to the lowprevalenceofACC,most reports arebasedonvery
small patient populations or single-institution retrospective
series.[5,11–13] The few population-based studies that are available
wereestablished intheUnitedStates,Europe,andDenmarkfromthe
Surveillance, Epidemiology and End Results, EUROCARE-3, and
Danish Head and Neck Cancer Group databases[8–10,14] which all
demonstrated the importance of staging on the survival of
ACC.[8–10,14]Marginstatus,[10]ageatdiagnosis,[8,10]nodalstatus,[8]
T classiﬁcation,[8] gender,[9] and primary site[8,9] from these studies
were mentioned as independent factors to survival. Unfortunately,
only 1 of the 4 population-based studies identiﬁed risk factors
concerning LR recurrence,[10] which included staging, margin
Table 1
Tumor clinicophathological features.
Characteristics No. of patients, %
Primary site
Parotid 53 (23.2)
Submandibular 44 (19.3)
Sublingual 11 (4.8)
Floor of mouth 20 (8.8)
Hard/soft palate 67 (29.4)
Sinonasal tract 8 (3.5)
Buccal 5 (2.2)
Retromolar 3 (1.4)
Mobile tongue 9 (3.9)
Base of tongue 5 (2.2)
Mandible 3 (1.3)
T classiﬁcation
T1 58 (25.4)
T2 103 (45.2)
T3 46 (20.2)
T4 21 (9.2)
N classiﬁcation
N0 207 (90.8)
N1,2 21 (9.2)
M classiﬁcation
M0 218 (95.6)
M1 10 (4.4)
Tumor size
4cm 183 (80.3)
>4cm 45 (19.7)
Stage
I–II 147 (64.5)
III–IV 81 (35.5)
Perineural/nerve invasion
Yes 71 (31.1)
No 157 (68.9)
Margin status
Positive/close 95 (41.7)
Negative 133 (58.3)
Lymphovascular invasion
Yes 12 (5.3)
No 216 (94.7)
Histologic pattern
Cribriform or tubular 161 (70.7)
Solid 67 (29.3)
Ouyang et al. Medicine (2017) 96:5 Medicinestatus, and vascular invasion as signiﬁcant variables.However, risk
factors related to DM were not reported in these trials.
The aim of the present study was to report a cohort of sizable
patients with salivary glands ACC of the head and neck whowere
previously untreated in South China and to investigate predictors
for LR recurrence, DM, and survival.
2. Patients and methods
2.1. Study design
We retrospectively reviewed all the records for patients with
salivary glands ACC of the head and neck whowere treated at Sun
Yat-sen University (Guanghua Hospital of Stomatology, Sun Yat-
en University Cancer Center, Sun Yat-senMemorial Hospital, and
The First AfﬁliatedHospital), from1990 to 2015. From the pooled
data, 228 patients who underwent deﬁnitive surgical treatment
were eligible for the study. Demographic data, clinical character-
istics, and follow-up information were recorded. TNM classiﬁca-
tion and clinical staging were documented according to the
American Joint Committee on Cancer staging criteria.[15] Surgical
margin status was recorded from the pathological reports in the
medical records. According to NCCN clinical practice Guidelines
in Oncology, Head and Neck Cancers (Version I, 2015),[16] a clear
margin is deﬁned as the distance from the invasive tumor front that
is 5mmormore from the resectedmargin; a closemargin is deﬁned
as the distance from the invasive tumor front to the resectedmargin
that is less than 5mm; a positive margin is deﬁned as carcinoma in
situ or as invasive carcinoma at the margin of resection.
InstitutionalReviewofBoard approvalwas obtained for this study.
A head and neck pathologist reviewed all the pathological slides.
Histologic information including the tumor subtype (cribriform,
tubular, or solid), perineural/nerve invasion, lymphovascular
invasion, and nodal status were recorded. Margin status was
collected from medical records. When >30% of tumor was
presented as a solid component, it was classiﬁed as a solid pattern.
2.2. Treatment
All patients underwent surgery as deﬁnitive treatment. The
indications for postoperative radiotherapy (RT) included late-
stage tumors (stage III–IV), close/positive margins, perineural/
nerve invasion, and lymphovascular invasion. Of the 228 patients,
104 patients (45.6%) received postoperative RT. The average
radiation dose delivered to the primary site was 59.3Gy (range
18–75Gy). In brief, the prophylactic irradiation dosewas 46 to 50
Gy, with a 60 to 66Gy boost to high-risk areas. For patients with
adverse factors such as positive margins, the dose of radiation was
over 66Gy. Two patients withdrew from postoperative RT due to
acute toxicity at 18 and 54Gy. Due to poor general health or
refusal, 14/95 patients with positive/close margins and 17/81
patients with stage III–IV disease did not receive postoperative RT.
Nineteen patients with nodal disease, local recurrence, or DM
received chemotherapy, each with different regimens.
2.3. Statistical analysis
Estimated survival rates and curves describing survival were
generated using the Kaplan–Meier method. Statistical signiﬁcance
of the differences between certain curves was determined using the
log-rank test.Correlationsbetween clinicopathological factors and
the outcomes were analyzed using a Cox proportional hazards
regression model. A 2-tailed P value of <0.05 was considered
signiﬁcant. Statistical analyses were performed with SPSS (version
22.0; IBM Corporation, Somers, NY) software application.23. Results
3.1. Demographic data and clinicopathological
characteristics
The cohort consisted of 99 males and 129 females with a median
age of 48 years at diagnosis (range, 13–78 years). The peak
incidence was during the 5th decade of life, accounting for 28.9%
(66/228) of all tumors.
Almost all the patients (218/228, 95.6%) presented with a
gradually growing mass. Other incidental symptoms included
facial paralysis (3.5%), sensory/motor neural deﬁcit (3.9%),
rapid tumor growth (6.1%), ulceration with/without bleeding
(3.5%), tooth mobility (3.9%), and nasal obstruction (3.1%).
The course of disease ranged from 2 months to 11 years.
Of the 228 tumors, 120 (52.6%) originated from the minor
salivary glands, and 108 (47.4%) occurred in the major salivary
glands. The palate (67/228) was the most frequently affected site,
followed by the parotid gland (53/228) and the submandibular
gland (44/228) (Table 1).
Table 2
Follow-up results with local-regional recurrence and distant
metastasis information.
Characteristics No. %
Local-regional recurrence 58 (27.6)
Local recurrence 52 (24.7)
Regional nodal disease 16 (7.6)
Distant metastasis 64 (30.5)
Lung 55/64 (85.9)
Liver 12/64 (18.8)
Bone 3/64 (4.7)
Brain 4/64 (6.3)
Ouyang et al. Medicine (2017) 96:5 www.md-journal.comAt the time of diagnosis, 57 patients (25.0%) presented with
stage I disease, 90 patients (39.4%) with stage II disease, 46
patients (20.2%) with stage III disease, and 35 patients (15.4%)
with stage IV disease. Twenty-one patients (9.2%) were detected
with pN+ classiﬁcation and 10 patients (4.4%) with M1 disease
all metastasizing to the lung at initial treatment. Histologically,
161 tumors (70.7%) were identiﬁed as cribriform or tubular
growth pattern, and 67 (29.3%) solid pattern. Other clinical and
histologic features were presented in Table 1.3.2. Follow-up information
Regular follow-up visit was required every 3 months/6 months
within/beyond 5 years after treatment. A thorough head and neck
clinical examination was mandatory. Chest radiograph was
recommended every 6 to 12 months. MRI, CT, and/or PET-CT
were indicated if there was any suspicion of LR recurrence or
DM.
Follow-up information was available for 210/228 (92.1%) of
the patients. Follow-up duration for living patients ranged from
12 to 288months (mean 74.6 months, and median 66.0 months).
At the end of the follow-up period, 70 patients had died: 17
patients died from LR recurrence, 33 of DM, 17 had both LR
recurrence andDM, and 3 of other causes. In total, LR recurrence
contributed to 34/67 (50.7%) of the disease-related death while
DM accounted for 50/67 (74.6%). A total of 140 (66.7%)
patients remained alive, including 32 patients with residual
disease. Fifty-one patients (26.7%) developed LR recurrence
(Table 2), where recurrence ranged from 2 to 176 monthsFigure 1. Kaplan–Meier survival curves of (A) overall su
3(median of 24 months) after the initial treatment. Fifty-four
patients developed DM from 3 to 212 months (median 37
months) after treatment of the primary disease. Including 10
patients who already had lung metastasis at diagnosis, total DM
rate is 30.5%. Patients with DM had a median survival time of
37.0 months. A total of 74% of the LR recurrence and 68.5% of
the DM were detected within 5 years after treatment.3.3. Survival analysis
The estimated median OS and median disease-free survival (DFS)
for all patients was 133 and 86 months, respectively. The
estimated 5-, 10-, and 15-year OS rates were 84.7%, 70.8%, and
34.0%, respectively. Five-, 10-, and 15-year DFS rates were
estimated at 59.7%, 38.0%, and 20.9%, respectively (Fig. 1).
Patients who developed LR-recurrence had a signiﬁcantly
lower median OS (104 months) than patients who did not have
LR-recurrence (172months; P=0.014). The estimated 5- and 10-
year OS in patients with no LR-recurrence were 86.1% and
72.2%, respectively, while patients with LR-recurrence were
81.2% and 32.5%, respectively (Fig. 2A). Similarly, the
estimated 5- and 10-year OS rates were signiﬁcantly lower in
patients with DM (69.7% and 29.0%, respectively) than those
who did not have DM (93.8% and 79.4%, respectively; P<
0.001) (Fig. 2B).
3.4. Risk factors for local-regional recurrence, distant
metastasis, and survival
Risk factors were analyzed using a Cox proportional hazards
regression model. Variables achieving signiﬁcance in the
univariate analysis were subsequently incorporated into multi-
variate analysis using Stepwise method. For OS, age >50 years
(P=0.010), T3–4 (P=0.001), N+ (P<0.001), M1 (P<0.001),
presence of lymphovascular invasion (P<0.001), perineural/
nerve invasion (P=0.038), and positive/close margin status (P<
0.001) were signiﬁcant predictors for decreased survival. Survival
was signiﬁcantly worse with tumor sites located in the ﬂoor of
month (FM)/sublingual area (SL)/tongue complex, sinonasal
tract, and hard palate compared to those in parotid, submandib-
ular gland (SG), and the “other” group (mandible, buccal, soft
palate, base of tongue, and retromolar region) (P<0.001).
However, gender (P=0.089), histologic patterns (P=0.396), andrvival and (B) disease-free survival of ACC patients.
Figure 2. Cumulative survival curves of ACC patients. (A) Overall survival was signiﬁcantly reduced in patients with LR recurrence (green line) compared with
patients without LR recurrence (blue line). P=0.014. (B) Overall survival was signiﬁcantly reduced in patients with DM. P<0.001. ACC=adenoid cystic carcinoma,
LR= local-regional, DM=distant metastasis.
Ouyang et al. Medicine (2017) 96:5 Medicinepostoperative RT (P=0.269) did not appear to inﬂuence OS
(Fig. 3). Furthermore, T3–4, N+, age >50 years, presence of
lymphovascular invasion, positive/close margin, primary tumor
location in FM/SL/tongue area, sinonasal tract, and hard palate
were identiﬁed as independent factors adversely affecting the OS
from the multivariate analysis (Table 3).
T3–4 (P=0.034), N+ (P=0.001), tumor location in the FM/SL/
tongue complex, sinonasal tract, and hard palate (P=0.047), and
lymphovascular invasion (P=0.003) were signiﬁcantly associat-
ed with a higher risk of LR recurrence (Fig. 3). Multivariate
analysis of these signiﬁcant factors revealed that T3–4 classiﬁca-
tion, positive nodal status, and presence of lymphovascular
invasion were independent factors correlated with LR recurrence
(Table 3).
Meanwhile, as shown in Fig. 3 and Table 3, signiﬁcant
parameters toward the development of DM included T3–4Figure 3. Summary of univariate analysis for LR recurrence, DM, and overall surviv
overall survival were: age (P=0.010), T classiﬁcation (P=0.001), N classiﬁcation (P
0.001), perinerual/nerve invasion (P=0.038), and lymphovascular invasion (P<0.0
(P=0.001), location (P=0.047), and lymphovascular invasion (P=0.003). Signiﬁca
(P<0.001), location (P=0.033), and lymphovascular invasion (P=0.011). s, solid;
ﬂoor of mouth, HP=hard palate, HR=hazard ratio, LR= local-regional, RT= radio
4classiﬁcation (P=0.028), positive/close margin (P<0.001),
lymphovascular invasion (P=0.011), and primary tumor site
located in FM/SL/tongue complex, sinonasal tract, and hard
palate (P=0.033). T3–4 classiﬁcation, the presence of lympho-
vascular invasion, and positive/close margin were each indepen-
dent risk factors for DM.4. Discussion
ACC is characterized by an indolent but persistent course by local
inﬁltrative growth and a high incidence of DM. Our ﬁndings
indicated that T3–4, presence of lymphovascular invasion, and
positive/close margins were independent risk factors for DM.
Meanwhile, LR recurrence was affected independently by T3–4,
presence of lymphovascular invasion, and N+ status. Besides the
factors mentioned above, multivariate analysis also revealedal. HR and 95% CI of HR were showed in Forest plot. Factors of signiﬁcance for
<0.001), M classiﬁcation (P<0.001), location (P<0.001), margin status (P<
01). For LR-recurrence they were: T classiﬁcation (P=0.034), N classiﬁcation
nt factors for DM development were: T classiﬁcation (P=0.028), margin status
c, cribriform; t, tubular. CI=conﬁdence interval, DM=distant metastasis, FM=
therapy, SL=sublingual, ST=sinonasal tract.
[14]
Table 3
Summary of multivariate analysis for overall survival, local-regional control, and distant metastasis control.
Overall survival LR control DM control
P HR (95%CI) P HR (95%CI) P HR (95%CI)
T3–4 <0.001 3.0 (1.7–5.3) 0.001 2.8 (1.5–5.2) 0.008 2.3 (1.2–4.3)
N+ 0.002 5.3 (1.8–15.5) 0.001 4.2 (1.8–9.7)
Lymphovascular invasion (+) 0.003 6.0 (1.8–19.9) 0.032 3.7 (1.1–12.0) 0.017 3.6 (1.3–10.4)
Margins (+) 0.006 2.3 (1.3–4.1) 0.001 3.0 (1.5–5.8)
Location (FM/SL/tongue, HP, ST) 0.041 1.9 (1.0–3.7)
CI= conﬁdence interval, DM=distant metastasis, FM= ﬂoor of mouth, HP=hard palate, HR=hazard ratio, LR= local-regional, SL= sublingual, ST= sinonasal tract.
Ouyang et al. Medicine (2017) 96:5 www.md-journal.comlower survival rates among patients with tumors located in FM/
SL/tongue, hard palate, and sinonasal tract compared to tumors
originating from with the parotid, submandibular gland, buccal,
base of tongue, and soft palate.
The present study highlighted lymphovascular invasion as a
strong independent variable associated with survival, LR recur-
rence, and DM. Oplatek et al[17] and Min et al[18] both reported
similar observations that lymphovascular invasionpresented in the
head and neckACCwas independently associatedwith LR failure.
Thompson et al[19] suggested patients with sinonasal tract and
nasopharyngeal ACC demonstrating lymphovascular invasion
had an increased incidence of recurrence and lower survival
probability. Therefore, pathological diagnoses of ACC should
place emphasis on detecting lymphovascular invasion. Once a
patient is found to have lymphovascular involvement, close
monitoring and periodical chest radiographs for detecting DMs
should be strictly implemented. In our own practice, chest
radiograph was recommended every 6 to 12 months. Multidisci-
plinary treatment should also be considered in these patients.
The ﬁndings of the present study conﬁrmed T3–4 classiﬁcation
rather than disease staging[9–11,14] was predictor for lower
survival. Moreover, multivariate analysis also identiﬁed T3–4 as
another independent risk factor for both LR recurrence and DM.
We recorded a rate of 9.2% on initial presentation with an
additional 7.6% developing positive lymph nodes subsequently.
The rate of lymph node involvement over the course of the disease
was 12.3%. These rates were comparable to other studies.[6,8,18]
In concurrence with other reports, our study also determined that
positive nodal status was an independent predictor for worse
prognosis, adversely affecting the LR control and surviv-
al.[17,18,20] Whether nodal status has an inﬂuence on DM
development is controversial. Previously, Bhayani et al[21] found
positive lymph nodes on neck dissection and lymph nodes with
extracapsular spread had statistically signiﬁcant correlations
with the development of DM in early-stage ACC. However, in
our cohort, we failed to conﬁrm that nodal status had an
inﬂuence on DM development, which was consistent with Zhang
report.[13] Due to the low incidence of nodal metastasis, so far
there is no consensus on the relationship between nodal status
and DM development, and further investigation is warranted.
Although many authors reported histopathological subtype
was a major predictor for LR recurrence,[13] DM,[21] and
survival,[11,13,22,23] we did not ﬁnd such a correlation in our
study. Tumor subtypes (solid/cribiform/tubular pattern) achieved
nonsigniﬁcant results in the univariate analysis and the Cox
multivariate analysis, suggesting that subtypes have no impact on
LR recurrence, DM development, or survival. Our results are
consistent with data from Spiro et al[6,12] as they also could not
conﬁrm the impact of solid subtype on prognosis. Unfortunately,
the limited information provided from the 3 population-based5studies from the EUROCARE-3 and Surveillance, Epidemiol-
ogy and End Results[8,9] databases neither cannot provide a
conclusive correlation whether tumor subtype inﬂuences surviv-
al. Therefore, until there is more clinical evidence in the future,
whether a different pathological subtype affects ACC prognosis
currently is still controversial.
The present study revealed that positive/close margin was
independent predictor forDMandOS,which is consistentwith the
ﬁndings fromother studies.[8,9] Interestingly, margin status did not
seem to impact LR recurrence in our ﬁndings. Unexpectedly our
results have suggested that perineural/nerve invasion has no
signiﬁcant inﬂuence on recurrence, metastasis, or survival. Amit
et al[24] have reported intraneural rather than perineurral invasion
as a factor trending for poor prognosiswhileGarden et al[25] found
that perineural invasion was an adverse prognostic factor only
when a major (named) nerve invasion was involved. This
inconsistency raises the necessity for further research on the
effects of different patterns of nerve invasion of ACC.
Our results indicated that tumors originating from the FM/SL/
tongue area, sinonasal tract, and hard palate were adverse
predictors for survival. This may be due to the following reasons:
ﬁrst, the complex anatomy of these areas increases the difﬁculty
of surgery planning and treatment implementation, and surgery
approaches to the advanced tumors in these locations are
complicated; second, tumors originating from these sites usually
present an indolent and asymptomatic course, which leads to the
delayed patients’ help seeking process; third, the frequent
movement of the mobile tongue may increase the risk of nodal
involvement; and last, advanced-stage hard palate and sinus ACC
may involve skull base and cranial nerves. However, we found no
signiﬁcant differences of the recurrence, DM, and survival
outcome between major and minor salivary glands.
Age appears to impact survival, as several authors reported
worse survival in older patients with ACC[13,21] which is
consistent to our univariate analysis results where age at
diagnosis had a signiﬁcant inﬂuence on survival and DM. Since
ACC is characterized by an indolent but persistent clinical course,
older patients are more likely to present with late-stage tumors
that are more prone for recurrence and DM.[14] Also, older
patients are more likely to suffer from other existing comorbid-
ities which may limit their treatment response and tolerance for
an aggressive multidisciplinary approach compared to younger
patients. However, in the multivariate analysis, age was not an
independent factor for ACC prognosis.
Long-term outcome of ACC patient did not improve over
time.[14] Treatment modalities are limited and have not reached a
universal consensus. However, current standards indicate
surgery as ﬁrst choice for treatment with the aim to obtain free
margins. RT is usually indicated for local disease control
following surgery, and used alone for patients with nonresectable
[3] Coca-Pelaz A, Rodrigo JP, Bradley PJ, et al. Adenoid cystic carcinoma of
Ouyang et al. Medicine (2017) 96:5 Medicinetumors or those who cannot tolerate surgery. Although the role of
RT in ACC treatment is still controversial, postoperative RT is
reported to be widely implemented in up to 75% to 100% of
ACC cases.[10,13,21] Surprizingly, in our analysis, the inclusion of
postoperative RT did not appear to impact LR recurrence, DM,
or OS (Fig. 3). However, our results must be interpreted carefully
since there are multiple covariables that need to be considered
before such a conclusion can be made including irradiation
technique, dosage, and patient compliance. The role of chemother-
apy is still currently a subject of debate as there is no deﬁnitive
protocol established for ACC treatment. Currently limited
evidences showed that mitoxantrone or vinorelbine is both
reasonable 1st-line single-agent options, while cisplatin and
anthracycline are recommended for combination chemotherapy.[1]
Identifying novel targets and individualized chemotherapies
directed at the key genes involved in the tumorigenesis of ACC
offers a potential treatment option for chemotherapy to help
improve ACC survival. Given the low incidence of ACC,
performing prospective randomized controlled clinical trialswould
be very difﬁcult. A lack of high-level clinical evidence will continue
to be an obstacle for treatment planning and decision-making.
There were a number of limitations in our present study. Our
study does not offer the highest level of clinical evidence since it is
a retrospective study design. Furthermore, considering the study
covered a time period of 25 years, heterogeneity of treatments
including the extent of surgery, postoperative RT, and
chemotherapy should be taken into account. Given these
short-comings, large-scale prospective studies are warranted
before reaching ﬁnal conclusions.5. Conclusions
The presence of lymphovascular invasion and a high T
classiﬁcation were very strong adverse factors and independent
predictors for ACC patients’ prognosis including LR control, DM
control, and survival. Positive nodal status also adversely
impacted the LR control and survival. Positive/close margin
was another independent predictor for DM and survival.
Furthermore, prognosis was also modiﬁed by location of the
primary site. ACC patients with such risk factors should be more
carefully managed during treatment and follow-up.
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